Hafnia alvei HA4597™对减重手术后体重减轻与血糖控制的影响——三盲、区组随机、12个月、平行组、安慰剂对照临床试验的研究方案
该研究方案拟在三盲、区组随机、平行组、安慰剂对照设计中,评估Roux-en-Y胃旁路术后补充Hafnia alvei HA4597™(每日2粒,相当于5×10^7 CFU,共90天)对术后1年体重减轻与血糖控制的影响;主要结局为超重体重减少量和糖化血红蛋白,同时评估代谢与炎症指标、肠道菌群组成及代谢物、胃肠道生活质量;研究在里斯本Hospital CUF Tejo招募18至65岁、BMI≥35 kg/m2且至少合并一种严重肥胖相关 comorbidity 或BMI≥40 kg/m2的患者。
要点
- 该方案评估Roux-en-Y胃旁路术后补充Hafnia alvei HA4597™对术后1年体重与血糖控制的作用。
- 干预为每日2粒Hafnia alvei HA4597™(相当于5×10^7 CFU)或安慰剂,持续90天,三盲、区组随机、平行组设计。
- 主要结局为超重体重减少量和糖化血红蛋白,评估时间点为基线及术后3、6、9、12个月。
核心结论
- 该研究将提供严重肥胖个体肠道菌群特征的信息,并识别Hafnia alvei HA4597™作为辅助治疗在术后1年维持代谢与体重控制方面的风险/获益比。
研究设计与样本
- 三盲、区组随机、平行组、安慰剂对照临床试验方案,计划比较Roux-en-Y胃旁路术后补充Hafnia alvei HA4597™与安慰剂的效果。
- 研究对象为在里斯本Hospital CUF Tejo接受Roux-en-Y胃旁路术的患者,入组条件为18至65岁、BMI≥35 kg/m2且至少合并一种严重肥胖相关 comorbidity,或BMI≥40 kg/m2。
- 干预为每日服用2粒Hafnia alvei HA4597™(相当于5×10^7 CFU)或安慰剂,持续90天。
- 评估时间点为基线及术后3、6、9、12个月。
关键数值与推荐
- 主要结局为超重体重减少量和糖化血红蛋白。
- 次要评估包括其他代谢与炎症结局、肠道菌群组成与代谢物、胃肠道生活质量的变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Subjects with obesity exhibit changes in gut microbiota composition and function (i.e. dysbiosis) that contribute to metabolic dysfunction, including appetite impairment. Although bariatric surgery is an effective treatment for obesity with a great impact on weight loss, some subjects show weight regain due to increased energy intake after the surgery. This surgery involves gut microbiota changes that promote appetite control, but it seems insufficient to completely restore the obesity-associated dysbiosis - a possible contributor for weight regain. Thus, modulating gut microbiota with probiotics that could improve appetite regulation as a complementary approach to post-operative diet (i.e. Hafnia alvei HA4597™), may accentuate post-surgery weight loss and insulin sensitivity. METHODS: This is a protocol of a triple-blinded, blocked-randomized, parallel-group, placebo-controlled clinical trial designed to determine the effect of Hafnia alvei HA4597™ supplementation on weight loss and glycaemic control 1 year after bariatric surgery. Patients of Hospital CUF Tejo, Lisbon, that undergo Roux-en-Y gastric bypass are invited to participate in this study. Men and women between 18 and 65 years old, with a BMI ≥ 35 kg/m2 and at least one severe obesity-related comorbidity, or with a BMI ≥ 40 kg/m2, and who are willing to take 2 capsules of Hafnia alvei HA4597™ probiotic supplements (equivalent to 5 × 107 CFU) vs. placebo per day for 90 days are included in this study. Assessments are carried out at baseline, 3, 6, 9, and 12 months after the surgery. Loss of weight in excess and glycated haemoglobin are considered primary outcomes. In addition, changes in other metabolic and inflammatory outcomes, gut microbiota composition and metabolites, as well as gastrointestinal quality of life are also being assessed during the trial. DISCUSSION: The evidence obtained in this study will provide relevant information regarding the profile of the intestinal microbiota of individuals with severe obesity and the identification of the risk/benefit ratio of the use of Hafnia alvei HA4597™ as an adjunctive treatment in the maintenance of metabolic and weight control one year after the surgical intervention. TRIAL REGISTRATION: ClinicalTrials.gov NCT05170867. Registered on 28 December 2021.
引用
- Ismael S, Vaz C, Durão C, et al. The impact of Hafnia alvei HA4597™ on weight loss and glycaemic control after bariatric surgery - study protocol for a triple-blinded, blocked randomized, 12-month, parallel-group, placebo-controlled clinical trial. Trials. 2023. PMID: 37248499. doi:10.1186/s13063-023-07383-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。